Clinical Trials Logo

Embolism clinical trials

View clinical trials related to Embolism.

Filter by:

NCT ID: NCT02597218 Recruiting - Pulmonary Embolism Clinical Trials

Incidence of Venous Thromboembolic Disease and Portal Vein Thrombosis After Hepatectomy. A Cohort Study.

Start date: October 2015
Phase:
Study type: Observational

Observational. Retrospective cohort.

NCT ID: NCT02460952 Recruiting - Pulmonary Embolism Clinical Trials

The Clinic Study to Prevent Pulmonary Embolism in Patients With General Anesthesia Operation in Perioperative Period

Start date: August 2014
Phase: N/A
Study type: Observational

The purpose of this study is to investigate the prevention of Pulmonary Embolism in Patients who With General Anesthesia Operation in Perioperative Period.

NCT ID: NCT02410941 Recruiting - Pulmonary Embolism Clinical Trials

Improving the Stewardship of Diagnostic Imaging Resources in Alberta Emergency Departments

Start date: January 2016
Phase: N/A
Study type: Interventional

Utilization of diagnostic imaging in the Emergency Department has increased dramatically over the past two decades, driven by an increased availability of advanced imaging, legal pressures to exclude serious diagnoses in low-risk patients, patient expectations, and the tendency to associate more testing with a higher quality of care. However, this rise in the use of diagnostic imaging, particularly in low-risk patients, may not be taking into account the risk of radiation exposure to patients, or the impact on finite health system resources. The objective of this project is to improve the appropriateness of CT imaging in Alberta Emergency Departments by advancing awareness of, and adherence to, evidence-based guidelines for CT imaging of patients with mild traumatic brain injury (MTBI) and suspected pulmonary embolism (PE). These two clinical scenarios have been selected because of evidence of significant variation in imaging practices across Alberta, and the robust evidence base that exists to guide CT imaging decisions such as the Canadian CT Head Rule and the Pulmonary Embolism Rule Out Criteria.

NCT ID: NCT02340741 Recruiting - Air Embolism Clinical Trials

Insufflation of Carbon Dioxide During Cardiac Surgery as Prevention Neurologic Complications

Start date: September 2014
Phase: N/A
Study type: Interventional

Effect of intraoperative insufflation of carbon dioxide on the neurologic complications in the early postoperative period after open cardiac surgery.

NCT ID: NCT02268903 Recruiting - Clinical trials for Pulmonary Embolism With Right Ventricle Enlargement

Diuretic Versus Placebo in Pulmonary Embolism

DiPER
Start date: April 13, 2015
Phase: Phase 3
Study type: Interventional

Pulmonary Embolism (PE) is a frequent and severe disease with an annual incidence of about 75000 cases in France and a short-term mortality rate of about 10%. Death is usually related to an acute right ventricular (RV) failure due to the increase in right ventricular afterload. Treatment of PE with RV failure consists in fluid expansion and thrombolysis in case of shock. However several studies suggest that fluid expansion may worsen acute RV failure by increasing RV dilatation and ischemia and left ventricular compression by RV dilatation. Thus, current guidelines regarding PE treatment remain unclear about the use of fluid expansion. In a preliminary study published by our group, we showed that diuretic treatment in the setting of PE with RV dilatation is safe and is associated with an increase in urine output, a decrease in heart rate and an increase in SpO2 in normotensive patients with oliguria. This may be related to the decrease of ventricular interdependence and enhancement of both LV and RV function. The main objective of the study is to evaluate the 24-hours clinical benefit of furosemide in patients referred for acute PE with RV dilatation compared to placebo. The combination of urine output and sPESI clinical parameters reflects hemodynamic status. It is relevant as it indicates the disappearance of pre-shock symptoms and is therefore associated with a lower event risk. Thus, it allows early discharge of the patients from the intensive care unit.

NCT ID: NCT02156401 Recruiting - Clinical trials for Venous Thromboembolism (VTE)

VTEval Project - Prospective Cohort Studies to Evaluate and Improve Diagnostics, Management Strategies and Risk Stratification in VTE

VTEval
Start date: April 2013
Phase:
Study type: Observational

Venous thromboembolism (VTE) with its two clinical manifestations deep vein thrombosis (DVT) and pulmonary embolism (PE) is a life-threatening disease that is associated with considerable morbidity and mortality. The incidence of VTE increases with age and it - as the third most common cardiovascular disease after ischemic heart disease and stroke - represents an important public health problem in industrialized countries with several aspects in need to be addressed. VTEval Project includes three long-term prospective observational studies to evaluate and improve VTE diagnostics and management, treatment and outcome. The aims of the project include a systematic assessment of VTE, i.e. disease status (symptoms, clinical and subclinical aspects) and risk profiles (classic, psychosocial and environmental factors), using a system-oriented approach. VTEval collects three large prospective cohorts of patients with suspected and incident VTE consisting of individuals with a clinical suspicion of acute PE, individuals with a clinical suspicion of acute DVT, and individuals with incidental diagnosis of VTE). The standardized and harmonized data acquisition of the study establishes a sustainable resource for comprehensive research on VTE, thus providing the basis for both short- and long-term analysis.

NCT ID: NCT02128178 Recruiting - Pulmonary Embolism Clinical Trials

Laparoscopic Bariatric Surgery: Two Regimens of Venous Thromboprophylaxis: Prospective Randomized Study

Start date: November 2013
Phase: Phase 1/Phase 2
Study type: Interventional

Obese patients undergoing bariatric surgery warrant VTE prophylaxis because they are at high risk for developing a fatal pulmonary embolism or postthrombotic syndrome. However, a consensus does not exist on the most effective prophylactic approach.

NCT ID: NCT02029456 Recruiting - Pulmonary Embolism Clinical Trials

Low Dose Prolonged Infusion of Tissue Type Plasminogen Activator Therapy in Massive Pulmonary Embolism

Start date: June 2011
Phase: Phase 4
Study type: Interventional

The aim of the present study was to assess the effects of low-dose (25mg) prolonged administration (in 6 hours) of tissue type plasminogen activator (tPA) on in-hospital mortality and outcomes in patients with massive PE.

NCT ID: NCT01878539 Recruiting - Atrial Fibrillation Clinical Trials

Oral Anticoagulation and Self-management

Start date: June 2012
Phase: N/A
Study type: Interventional

An intervention program targeting patients and caregivers based on education about their condition and training in the use of portable coagulomenter to self monitor and training on the treatment adjustment to self manage, can be effective to enable patients in OACs to self manage as well as to identify determinant factors associated with the success and failure of the program.

NCT ID: NCT01823185 Recruiting - Clinical trials for Coronary Artery Disease

Bedside Testing of CYP2C19 Gene for Treatment of Patients With PCI With Antiplatelet Therapy

Start date: March 2013
Phase: Phase 4
Study type: Interventional

Clopidogrel is crucial as antiplatelet treatment in patients undergoing percutaneous coronary intervention (PCI) with stent implantation and during one year after PCI, to prevent atherothrombotic complications. However, clopidogrel is ineffective in certain patients due to genetic mutation in CYP2C19 gene a specific enzyme in the liver required for metabolism of clopidogrel. Therefore, the purpose of this study is to test these patients genetically at bedside and prescribe an alternative drug such as Ticagrelor (90 mg twice daily) or prasugrel ( 10mg once daily or 5mg once daily if the patient older than 75 years or a body weight < 60kg) if they are carriers of the allele 2 or 3 of the mutated gene.